Hydrogène de France Announces the World's First Plant for Mass Production of High-Powered Fuel Cells (Over 1 MW)
10.12.2019 23:00:00 EET | Business Wire | Press release
Hydrogène de France (HDF) becomes a French industrial company by launching its high-powered fuel cell production plant in Bordeaux. This plant, with an annual production capacity of 50 MW, will be the first in the world to mass produce high-powered PACs (greater than 1 MW) using PEM (Proton Exchange Membrane) technology. The industrialization and standardization of these systems reduces their cost and improves significantly their reliability and maintenance.
This plant will produce under the brand name "HDF Industry". It will integrate the Fuel Cell stacks of Canadian company Ballard, which today has the most widely deployed technology in the world. This exclusive worldwide agreement allows HDF to offer high-powered FCs whose performance and prices are adapted to the energy market.
A worldwide ambition
HDF intends to play a pioneering role in the emerging hydrogen market. Hydrogen, considered by both industrialists and governments as one of the solutions for the energy transition, is developing in multiple directions, including mobility as well as stationary applications.
HDF's vision is based on the development of hydrogen as a fuel and a vehicle for storing electricity. Renewable energies have conquered a place in the world of energy by overcoming the challenge of competitiveness. HDF believes that the time has come to take on the next challenge, that of intermittency.
An industrial reality
HDF started its industrial program 3 years ago consulting the world's leading fuel cell companies. Ballard was selected as being the ideal partner, as they have demonstrated their experience, industrial capacity and stack lifetime. HDF's industrial plan has been developed with the ClearGen and CEOG projects and with the expertise of its employees.
The HDF Industry plant will have a production capacity of 50MW of Fuel Cell per year within 5 years.
Benefiting from Ballard's know-how and HDF's unique experience in industrial hydrogen projects, this French multimegawatt fuel cell plant has a sizeable lead in the market.
Damien Havard, President and Founder of HDF:
We are particularly pleased with this cooperation with Ballard. HDF industrializes reliable FCs at a price adapted to the market. The standardization of this strategic brick will allow the production of non-polluting and competitive electricity on a large scale. HDF provides the industrial solution that was missing to develop the massive storage of renewable energy. Our market is huge: this is the end of the intermittency of renewable energies!
About Hydrogène de France: industrialist and developer of Renewstable® power plants
A specialist in hydrogen technologies, HDF develops, finances, builds and operates multimegawatt industrial power generation infrastructures.
A pioneer in its sector of activity, HDF achieved a world first in 2019 in Martinique, the ClearGen project: the installation and commissioning of a high-powered fuel cell (1 MW), using the hydrogen co-produced by the SARA refinery by transforming it into electricity. This project is funded by Europe (FCH-JU) and SARA.
HDF marketed the Renewstable® power plants, which capture intermittent renewable energy and store it massively in the form of hydrogen to produce stable, 24-hour electricity that can be controlled like a thermal power plant at a competitive price. The first Renewstable® power plant is developed in French Guiana, in collaboration with the French infrastructure fund Meridiam and SARA: the CEOG power plant is the largest in the world storing massively renewable energy via hydrogen, to produce stable and non-polluting electricity day and night for 10,000 households. CEOG will start its construction site in early 2020 and produce its first electrons in early 2022.
As an international player, HDF Energy currently has around ten Renewstable® projects in the advanced development phase in several countries.
- HDF Energy website: www.hdf-energy.com
- HDF Industry website: www.hdf-industry.com
- CEOG Power Plant Website: www.ceog.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005394/en/
Contact information
Investor and press relations:
- HDF: communication@hdf-energy.com / +33 (0)5 56 77 77 11 11
Agence 914
Salomé EON :
salome@agence914.fr
+33 6 78 86 66 48
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom